How COAPT’s ‘All or Nothing’ Trial Design Is Making Sense of a Messy Disease

Posted by Kate Templeton on October 12, 2018

Landmark. Groundbreaking. Blockbuster. All of these words, and then some, have been used to describe Abbott’s recent trial (COAPT) to support MitraClip’s indication expansion to include functional mitral regurgitation.

The trial decisively demonstrated that transcatheter mitral valve repair using MitraClip reduced hospitalizations for heart failure by 47% and all-cause two-year mortality by 38% when compared to medical therapy alone in patients with heart failure and severe functional mitral regurgitation (FMR). When the principal investigator, Dr. Greg Stone, announced the results to a standing-room-only crowd at TCT 2018 last month, the data was met with spontaneous applause.

Read More